Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione
- Development stage
- Preclinical
- Lead developer
- University of Johannesburg
- Modality
- Small Molecules
01
Overview
7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione is a small molecule compound isolated from the methanolic extract of *Carpobrotus edulis* (commonly known as sour fig). It is currently being investigated for its potential anticancer properties, specifically against pancreatic cancer. Research presented at AACR 2026 indicates that the compound induces apoptosis in MIA PaCa2 pancreatic cancer cells by activating the extrinsic TNF-mediated apoptotic pathway. Mechanistic studies, including protein-ligand docking, suggest that the compound has a high binding affinity for several key apoptotic and signaling proteins, including the Tumor Necrosis Factor Receptor (TNFR), Fas-associated protein with death domain (FADD), p53, Bak1, and Signal Transducer and Activator of Transcription 3 (STAT3). Preclinical assays have demonstrated that the compound selectively targets cancer cells while sparing non-cancerous MRC-5 cells, suggesting a favorable safety profile for further development.
- Other names
- 7,9-Ditert-butyl-oxaspiro [4.5] deca-6,9-diene-2,8-dione
02
Targets
BAKTP53 (Cellular Tumor Antigen p53 R175H)FADD (Fas-associated protein with death domain)STAT3 (Signal Transducer and Activator of Transcription 3)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)
Beyond the preview
Go deeper on 7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione.